NewLimit
NewLimit develops epigenetic reprogramming medicines designed to restore function in aging cells and treat age-related disease.
$435MSeries C
ParticipantN
NFDG
Activity from announced rounds
Activity in this selectionOct 25, 2026 · Biotech · Jan 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $450M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionShellworks
Develops bio-based plastic alternative materials for packaging and consumer goods
$15MSeries A
Role not disclosed